6,7-Seco-<i>ent</i>-Kauranoids Derived from Oridonin as Potential Anticancer Agents
作者:Shengtao Xu、Hong Yao、Mei Hu、Dahong Li、Zheying Zhu、Weijia Xie、Hequan Yao、Liang Wu、Zhe-Sheng Chen、Jinyi Xu
DOI:10.1021/acs.jnatprod.7b00057
日期:2017.9.22
6,7-seco-ent-kaurenes was developed. Herein, several novel spiro-lactone-type ent-kaurene derivatives bearing various substituents at the C-1 and C-14 positions were further designed and synthesized from the natural product oridonin. Moreover, a number of seven-membered C-ring-expanded 6,7-seco-ent-kaurenes were also identified for the first time. It was observed that most of the spiro-lactone-type
结构独特的6,7- seco- ENT -kaurenes,广泛分布于属香茶,已经吸引了,因为他们的抗肿瘤活性的极大关注。此前,市售冬凌草甲素(一种方便的转化1)至6,7- seco- ENT -kaurenes被开发。在此,从天然产物冬凌草甲素中进一步设计和合成了几种在C-1和C-14位置带有各种取代基的螺内酯型对映体-新戊烯衍生物。此外,一系列的7元C-环扩展-6,7- seco- ENT -kaurenes也被鉴定为第一次。据观察,大多数螺内酯型耳鼻喉科测试的β-天竺葵烯酮显着抑制癌细胞的增殖,IC 50值低至0.55μM 。对其作用机理的研究表明,代表性化合物7b在MCF-7人乳腺癌细胞中以低微摩尔水平影响细胞周期并诱导凋亡。此外,化合物7b在体内小鼠模型中抑制肝肿瘤生长,并且没有显示出可观察到的毒性作用。总的来说,这些结果值得对作为潜在的新型抗癌药的这些螺内酯型ENT-脲酮进行进一步的临床前研究。